SF3B1 mutations constitute a novel therapeutic target in breast cancer.
about
P1343
CIViC databaseDefective control of pre-messenger RNA splicing in human diseaseThe somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesLarge-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networksThe Novel Gene CRNDE Encodes a Nuclear Peptide (CRNDEP) Which Is Overexpressed in Highly Proliferating Tissues.Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 modelRNA splicing factors as oncoproteins and tumour suppressors.Histone H3K4 trimethylation: dynamic interplay with pre-mRNA splicing.Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1.Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures.Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.The isoflavone fraction from soybean presents mRNA maturation inhibition activity.Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.Genomic analyses identify molecular subtypes of pancreatic cancer.Depletion of three combined THOC5 mRNA export protein target genes synergistically induces human hepatocellular carcinoma cell death.Splicing-factor alterations in cancers.Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.RNA processing as an alternative route to attack glioblastoma.Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.Identifying and analyzing different cancer subtypes using RNA-seq data of blood platelets.Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.Modeling Myeloid Malignancies Using Zebrafish.Mutational landscape of RNA-binding proteins in human cancers.Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin.SF3B1 mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients.Gene aberration profile of tumors of adolescent and young adult females.Insights from structures of cancer-relevant pre-mRNA splicing factors.A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.Colorectal neoplasia differentially expressed: a long noncoding RNA with an imperative role in cancer.Splicing dysregulation as a driver of breast cancer
P2860
Q27612411-D8ED1089-CD1C-4B34-8C44-11CD4642B83DQ28077564-C6166ACA-B766-42CD-8213-F900FA6F921BQ28275430-82211936-BB71-4B91-A8A4-9A5F8AB4EE18Q28275692-DD1DCC46-7C7B-40BB-8FF7-7403C14039A8Q35632884-A3550FEF-8A47-4FF7-9110-74DB4517895CQ35822289-E45CDF06-117E-462E-8A19-C3C3D52EFD9BQ36254983-1216BD76-16A4-46F1-98B6-AC9264C18720Q36280761-F754D2E2-E587-4BCC-882B-811F91C4900DQ36466870-AB8A5AD4-32C8-4E64-B488-2E1EB425D5D4Q36549378-B4D9BADD-70DE-45C0-A1BF-383B647BCD72Q36895438-EDBF4C16-D6A1-461C-A1FC-A17B23F98744Q37371138-E4F0F84B-3A6D-4482-BD11-94F6A8BC2EF7Q37391660-AA97B701-F3FE-48CE-96D2-D5936D5C5087Q38583533-F40FF567-C4B0-4447-8D28-479AB61B3B69Q38712211-F0A05E3B-4010-400B-A1E4-187F6E0BB0E1Q38722694-207554D5-9D99-49D0-B7A5-3CCB07D3672CQ38725261-D04A40E3-AFC1-433D-9CF6-CE8901266998Q38737423-EAEFE5F7-BEBF-4467-9AE8-DA6C7A3744B0Q38766765-B73255B3-3FE3-4D86-9010-DF1848A2F9C0Q38769301-CE3E441F-8531-461B-9669-52668BD0F17DQ38791499-15D7B311-9C72-4EB9-925D-84192655DEFEQ38821041-935F6DD0-7DBE-4CFB-9F2B-E7BFE2012D23Q38929098-9A5728D3-9056-404D-A47C-75D5726019E3Q39217354-973BCF76-C2CD-4456-A467-5C3C961DB71BQ39368650-1D93F0F4-17B4-43AB-99D5-A5A9D81448B6Q39752527-2471AA99-1F27-4E26-BA72-1A11A8701249Q40151513-0064527D-3D9A-4635-AC65-BBB446C29B66Q42338844-C453944D-B2FB-4530-B1FE-C67403930135Q45943794-58AAA45B-912F-41C7-838E-F50F28AD3E22Q46430505-E0737CB2-D52D-4020-B630-4C9531C7532FQ47108992-C3E6ECA2-665B-403A-858B-117D1D1FE305Q47663665-BC05A423-A173-4BC3-8E69-8E35A0BDCDA7Q48235204-241B9EF2-9E71-4A68-BBB4-85803532DE20Q49569462-83A18B88-9DFA-440B-8148-8F97D99A7D08Q49787556-1F2F5B80-D89C-4DFF-944E-FACD1BB67105Q50057508-33E11397-9F32-47AF-BD66-2181BC2F00B2Q51220040-DE48BC0A-27C2-4E01-8B03-55EAF5523710Q52564290-3AF38673-3032-4948-AD38-DFA8AE5992C5Q55456641-508F6F80-2F82-425B-9433-678FE0F66FA4Q57106833-09DBF5B1-AF11-41CE-89F0-41661666FEF1
P2860
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@ast
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@en
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@nl
type
label
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@ast
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@en
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@nl
altLabel
SF3B1mutations constitute a novel therapeutic target in breast cancer
@en
prefLabel
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@ast
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@en
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@nl
P2093
P2860
P50
P3181
P356
P1476
SF3B1 mutations constitute a novel therapeutic target in breast cancer.
@en
P2093
Andri Leonidou
Anne-Vincent Salomon
Caterina Marchiò
Charlotte Ky Ng
P2860
P304
P3181
P356
10.1002/PATH.4483
P577
2015-03-01T00:00:00Z